David Ira Rosenthal
Affiliations: | Radiation Oncology | MD Anderson Cancer Center, Houston, TX, United States |
Google:
"David Rosenthal"Parents
Sign in to add mentor| Eli Glatstein | grad student | Penn | ||
| Joel Tepper | post-doc | UNC School of Medicine | ||
| (Resident at UNC) | ||||
Children
Sign in to add trainee| Clifton David Fuller | research assistant | 2002-2006 | MD Anderson Cancer Center |
| Amy C Moreno | post-doc | 2017- |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Koutroumpakis E, Mohamed ASR, et al. (2023) Longitudinal Changes in the Carotid Arteries of Head and Neck Cancer Patients Following Radiation Therapy: Results from a Prospective Serial Imaging Biomarker Characterization Study. Medrxiv : the Preprint Server For Health Sciences |
| Rooney MK, Andring LM, Corrigan KL, et al. (2023) Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio. Cancers. 15 |
| Roldan CJ, Rosenthal DI, Koyyalagunta D, et al. (2023) Methylene Blue for the Treatment of Radiation-Induced Oral Mucositis during Head and Neck Cancer Treatment: An Uncontrolled Cohort. Cancers. 15 |
| Sahin O, Wahid KA, Taku N, et al. (2023) Multi-Specialty Expert Physician Identification of Extranodal Extension in Computed Tomography Scans of Oropharyngeal Cancer Patients: Prospective Blinded Human Inter-Observer Performance Evaluation. Medrxiv : the Preprint Server For Health Sciences |
| Caudell JJ, Torres-Saavedra PA, Rosenthal DI, et al. (2022) Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics |
| Michikawa C, Torres-Saavedra PA, Silver NL, et al. (2022) Evolutionary Action Score of Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology. 7: 100989 |
| Gillison ML, Ferris RL, Harris J, et al. (2022) Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. International Journal of Radiation Oncology, Biology, Physics |
| Ng SP, Cardenas CE, Bahig H, et al. (2022) Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Current Oncology (Toronto, Ont.). 29: 6303-6313 |
| Kiong KL, Moreno A, Vu CN, et al. (2022) Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncology. 130: 105906 |
| Taku N, Chronowski G, Gunn GB, et al. (2022) Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology, Biology, Physics |